|[December 06, 2012]
Ken Phelps Set to Deliver Keynote Address for EPPIC Annual Conference
CINCINNATI --(Business Wire)--
Ken Phelps, one of the nation's leading experts in the 505(b)(2)
development pathway, will be a keynote speaker at the EPPIC
Annual Conference in San Francisco, January 6.
Titled "Repurposing of Drugs," his speech will look at opportunities
that sponsors have to develop niche products that can be developed with
dramatically lower costs using the 505(b)(2)
pathway to FDA approval.
"A 505(b)(2) non-disclosure agreement may also be eligible for
significant market exclusivity, depending on how it's developed," said
Phelps, president and CEO of Camargo
Pharmaceutical Servics. "That's a potential breakaway marketing
advantage that could be valuable to a lot of companies."
EPPIC was formed in 1998 by San Francisco Bay Area pharmaceutical and
biotechnology professionals to promote networking, create US-India life
science synergy and function as a resource for industry and academia.
This year's Annual Conference is titled "New Frontiers in Health Care
Sciences" and will be held from 8 a.m. to 7:30 p.m. Sunday, January 6,
at the Westin San Francisco Airport.
Phelps will also be hosting a webinar on 505(b)(2) for the
Pharmaceutical Education and Research Institute (PERI) titled "Fast and
Cost-Effective Drug Approval" December 13 from 3 to 4 p.m. EST. PERI is
an independent nonprofit dedicated to providing scientific and technical
continuing education for the pharmaceutical, biotechnology and medical
device industry. Visit http://peri.org/event-registration/ ee=53
About Camargo Pharmaceutical Services
Camargo Pharmaceutical Services is your full-service drug development
partner specializing in the 505(b)(2) process. Before development even
begins, we verify profit potential by working with your team to develop
a comprehensive program and timeline complete with important milestones
and cost objectives. We manage every facet of the plan throughout your
development continuum, from feasibility assessments, formulation and
testing the drug product, to conducting preclinical and clinical
studies, to final submission. Connect with Camargo on LinkedIn,
the President's blog
or visit www.camargopharma.com
for more information.
[ Back To Homepage ]